arrow_back Back to App

Increased Health Security: Funding the Fight Against Future Pandemics.

This law boosts funding and expands a federal program dedicated to developing new drugs and vaccines against unknown viruses that could cause the next pandemic. This ensures the US government is better prepared for a rapid response should a new, serious infectious disease emerge. Furthermore, the act requires that products developed with these funds be substantially manufactured within the United States.
Key points
Allocates an additional $40 million annually (2024-2028) for research into new manufacturing technologies for drugs and vaccines.
Focuses on developing flexible countermeasures that can work against entire families of viruses, rather than just one specific pathogen.
Requires that medical products developed under this program be predominantly manufactured in the US, strengthening domestic supply security.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_2093
Sponsor: Sen. Baldwin, Tammy [D-WI]
Process start date: 2023-06-21
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Disease X Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_2093.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-06-21.

What are the main provisions?

Key points include:

  • Allocates an additional $40 million annually (2024-2028) for research into new manufacturing technologies for drugs and vaccines.
  • Focuses on developing flexible countermeasures that can work against entire families of viruses, rather than just one specific pathogen.
  • Requires that medical products developed under this program be predominantly manufactured in the US, strengthening domestic supply security.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Baldwin, Tammy [D-WI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Public Investments